Videos

Factors Influencing Treatment Selection in Patients with MPNs

Ritu Salani, MD, describes the concordance between blinded independent central review and provider-assessed outcomes with dostarlimab among patients with advanced recurrent endometrial cancer in the phase 3 RUBY trial.

Advancing MDS Care: Novel Therapies and Recent Updates

An overview of myeloproliferative neoplasms (MPNs) followed by an exploration of available treatment options and addressing differences in approach based on MPN subtypes such as essential thrombocytopenia, polycythemia vera, and myelofibrosis.

Choosing Between BCMA and Non-BCMA Bispecifics in Multiple Myeloma Treatment

Insights concerning unmet needs in MDS treatment, ongoing trials, and recent updates in the treatment landscape.

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD

Recent Data on Non-BCMA Targeting Bispecifics in R/R MM

Experts explain the strategies for optimal selection between different BCMA-targeting and non-BCMA-targeting bispecifics for the treatment of relapsed/refractory multiple myeloma.

Surbhi Sidana, MD;Melissa Alsina, MD; Maria-Victoria Mateos, MD, PhD;Jack Khouri, MD

COMING SOON: Around the Practice: ctDNA Analysis to Direct Treatment Decisions in Colorectal Cancer

Experts review recent data on non-BCMA-targeting bispecifics for the treatment of R/R MM.

Tanios S. Bekaii-Saab, MD, an expert on colorectal cancer

Tanios S. Bekaii-Saab, MD, FACP

Selecting and Sequencing Non-BCMA-Targeting Bispecifics in MM

Tanios S. Bekaii-Saab, MD, provides a look at an upcoming Cancer Network Around the Practice program in which a panel of experts will present the case of a patient with colorectal cancer, review updates from clinical trials, and provide insights on the role of ctDNA in treatment decision-making.

Surbhi Sidana, MD;Melissa Alsina, MD; Maria-Victoria Mateos, MD, PhD;Jack Khouri, MD

Sequencing BCMA-Targeting Bispecifics in R/R MM Treatment

The panel discusses how non-BCMA-targeting bispecifics might be selected and sequenced in MM.

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD

Multiple Myeloma: Addressing Financial Barriers to Bispecifics

Cindy Varga, MD, details her experience with sequencing BCMA-targeting agents for patients with relapsed/refractory multiple myeloma.

Cesar Rodriguez, MD;Scott A. Soefje, PharmD;Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC;Frances A. Bell, NP

Bispecifics in MM: mSMART Guidelines for Monitoring and Managing AEs

Key opinion leaders in multiple myeloma management address barriers inherent in the selection and use of bispecifics.

Rafael Fonseca, MD;Shaji Kumar, MD, Mayo Clinic;Joselle Cook, MBBS, Mayo Clinic;Morie A. Gertz, MD, MACP, Mayo Clinic

Pharmacists’ Perspectives on Initiating Bispecific Therapy in Multiple Myeloma

Focused discussion on the mSMART guidelines for monitoring and managing adverse events associated with bispecific therapies in patients being treated for relapsed/refractory multiple myeloma.

Cesar Rodriguez, MD;Scott A. Soefje, PharmD;Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC;Frances A. Bell, NP

Insights from Experts at Mayo Clinic: Step-up and Treatment Dosing of Bispecifics

Experts Scott A. Soefje, PharmD, and Kirollos S. Hanna, PharmD, share their perspectives on initial steps in initiating bispecific therapy for patients with multiple myeloma.

Rafael Fonseca, MD;Shaji Kumar, MD, Mayo Clinic;Joselle Cook, MBBS, Mayo Clinic;Morie A. Gertz, MD, MACP, Mayo Clinic

Subset Analysis of the MAIA Study in the Frail Multiple Myeloma Population

A panel of key opinion leaders from Mayo Clinic reflect on optimizing use of bispecifics in relapsed/refractory multiple myeloma, reviewing step-up dosing, administration, and followup strategies.

Natalia Neparidze, MD;Noffar Bar, MD;Elan Gorshein, DO, JD, MPH;Catherine Wei, MD;David Witt, MD;Syed S. Ali, MD

Treatment Approaches in Patients With Transplant-Ineligible NDMM

Experts comment on the subset analysis of the MAIA study in the frail NDMM patient population.

Natalia Neparidze, MD;Noffar Bar, MD;Elan Gorshein, DO, JD, MPH;Catherine Wei, MD;David Witt, MD;Syed S. Ali, MD

Clinical Insights on the Treatment of Patients with High-Risk MDS

Noffar Bar, MD, discusses the MAIA study investigating a daratumumab combination therapy in patients with transplant-ineligible multiple myeloma.

An Introduction to MDS: Initial Diagnosis and Patient Risk Stratification

Dr. Daver reviews treatment goals and treatment options for patients with higher-risk MDS.

Positive Brexu-Cel Findings Raise Questions of Treatment Sequencing in B-ALL

Naval G. Daver, MD introduces myelodysplastic syndrome (MDS), focusing on the typical disease course, role of biomarker testing and risk stratification.

$Gregory W. Roloff, MD, indicates that brexucabtagene autoleucel did not yield significant positive findings in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who were MRD positive.$

Gregory W. Roloff, MD

June 25th 2023

Gregory W. Roloff, MD, indicates that brexucabtagene autoleucel did not yield significant positive findings in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who were MRD positive.

DEAR Study Offers ‘Hope’ to Patients With Non-Metastatic CRPC

Alicia K. Morgans, MD

Overview of Treatment Options for Relapsed/Refractory Multiple Myeloma

Alicia K. Morgans, MD, MPH, from Dana-Farber Cancer Institute indicates that patients with non-metastatic castration-resistant prostate cancer are able to stay on treatment for long periods of time with darolutamide vs enzalutamide and apalutamide.

Thomas G. Martin, MD;Ajay K. Nooka, MD;Jeremy Larsen, MD

Determining Transplant Ineligibility in Newly Diagnosed Multiple Myeloma

Key opinion leaders share comprehensive insight to the treatment armamentarium for patients with relapsed/refractory multiple myeloma.

Andrew P. Dalovisio, MD;Kelly Pippin, MD;Ryan P. Griffin, MD;Ernest C. Quintin, MD;Thomas Atkinson, MD

Features of High-Risk Multiple Myeloma and Clinical Trial Landscape

Focused discussion on factors that aid in determining transplant ineligibility when a patient presents with newly diagnosed multiple myeloma.

Al-Ola Abdallah, MD;Leyla O. Shune, MD;Nausheen Ahmed, MD;Jordan Snyder, PharmD

Treatment Options for Frontline and Relapsed Multiple Myeloma

The expert panel provides clinical insights on the key features of high-risk multiple myeloma and a look toward the clinical trial landscape.

C. Ola Landgren, MD, PhD;Dickran Kazandjian, MD;Benjamin Diamond, MD;Dennis Verducci, APRN

Overview of Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma

An overview of multiple myeloma treatment options in the frontline and relapsed settings.

Thomas G. Martin, MD;Ajay K. Nooka, MD;Jeremy Larsen, MD

What is the Role of Transplant in Treating Patients With NDMM?

Experts Thomas Martin, MD; Ajay Nooka, MD; and Jeremy Larsen, MD, provide a broad overview of cytokine release syndrome as it relates to the management of multiple myeloma.

Andrew P. Dalovisio, MD;Kelly Pippin, MD;Ryan P. Griffin, MD;Ernest C. Quintin, MD;Thomas Atkinson, MD

Patient Monitoring and Workup in Relapsed MM

Key opinion leaders in multiple myeloma management reflect on the current role of stem cell transplant in patients with newly diagnosed disease.

C. Ola Landgren, MD, PhD;Dickran Kazandjian, MD;Benjamin Diamond, MD;Dennis Verducci, APRN

Role of Transplant in Multiple Myeloma

Experts on multiple myeloma discuss approaches to laboratory workup and patient monitoring at the time of relapse.

Al-Ola Abdallah, MD;Leyla O. Shune, MD;Nausheen Ahmed, MD;Jordan Snyder, PharmD